FDA Considering Exclusivity Program As Antimicrobial Development Incentive
Executive Summary
A drug exclusivity program is being considered by FDA as an incentive to encourage investment in antimicrobial product development, FDA Commissioner Henney, MD, indicated during a Senate Appropriations/Labor, HHS & Education subcommittee hearing Sept. 20.
You may also be interested in...
Antimicrobial Drug Approval May Be Speeded By Enhanced Preclinical Studies
FDA should emphasize the use of preclinical studies to speed the approval of drugs that address antimicrobial resistance problems, an interagency task force report suggests.
Antimicrobials Labeling Rule Should Allow "Appropriate Use," PhRMA Says
FDA's proposed rule on labeling requirements for systemic antimicrobials should allow for "appropriate treatment" of infections that are suspected to be caused by susceptible microorganisms, the Pharmaceutical Research & Manufacturers of America said in comments to the agency.
Antimicrobial Drug Approval May Be Speeded By Enhanced Preclinical Studies
FDA should emphasize the use of preclinical studies to speed the approval of drugs that address antimicrobial resistance problems, an interagency task force report suggests.